Determining CVD Risk in RA

Kevin Deane, MD


December 07, 2010


This study used a unique cohort of patients with RA to demonstrate that both traditional CVD risk factors and RA severity may play a role in increased CVD risk. This study has several limitations, including a lack of evaluation of the contribution of acute-phase reactants or medications to CVD risk in this cohort. Also, we do not know from this study whether improving either traditional CVD risk factors or RA severity will result in improved overall CVD risk in patients with RA. However, as a take-home point, this study makes us aware that there may be modifiable risks for CVD in patients with RA, and it is likely reasonable to address these risks in order to improve outcomes. Going forward, we need randomized, controlled trials of CVD risk-factor modification in patients with RA in order to truly understand what we can do to improve the health of patients with RA.



Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: